FDA Alignment De-Risks CalciMedica’s Auxora Path in Acute Pancreatitis
FDA aligns with CalciMedica on Auxora Phase 2b endpoints for acute pancreatitis, de-risking the path to registration.
/ 2 items
FDA aligns with CalciMedica on Auxora Phase 2b endpoints for acute pancreatitis, de-risking the path to registration.
CalciMedica discontinues Phase 2 KOURAGE trial for acute kidney injury drug Auxora following safety concerns raised by independent committee monitoring the study.